Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00037843 · ClinicalTrials.gov registry record · Phase 3

Iodine I-131 Iodocholesterol, Its Use in Adrenal Screening

A Phase 3 study, sponsored by M.D. Anderson Cancer Center.

Completed
Registry status
Phase 3
Development phase
114
Enrollment target

NCT00037843: Completed Phase 3 study, sponsored by M.D. Anderson Cancer Center.

NCT00037843 is a Phase 3 study that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 114 participants. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00037843, a Phase 3 study, has completed, sponsored by M.D. Anderson Cancer Center.

COMPLETED
Registry status
Phase 3
Development phase
114 participants
Enrollment target

Study Summary

This is a clinical research study using I-131 Iodocholesterol which is an experimental radioactive chemical that when injected into the vein, is picked up in the adrenal glands and permits visualization with gamma imaging devices. These images are used in diagnosing a variety of adrenal abnormalities.Prior to the injection of I-131 Iodocholesterol, the patient will receive perchlorate capsules to block any uptake of I-131 by the thyroid gland if this is deemed important. The patient will continue to take these capsules throughout the period of imaging, which may last up to 1 week. The injection of I-131 Iodocholesterol will be given into a vein and the patient will return for images on at least 1 and possibly 2 occasions between 3-7 days after injection. If the case requires it, the patient may also be given a steroid in tablet form, dexamethasone, to take orally prior to and after the injection to suppress normal adrenal function so that the abnormal tissues can be more easily detected.

Interventions

  • DRUG I-131 Iodocholesterol

Trial Details

FieldValue
Enrollment Target 114 participants
Start Date 1988-12
Est. Completion 2007-08
Phase Phase 3

Sponsor

M.D. Anderson Cancer Center

2,692 total trials

What the Registry Record Tells You About NCT00037843

The ClinicalTrials.gov registry entry for NCT00037843 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 114 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 1 intervention - of which I-131 Iodocholesterol is the first listed.

NCT00037843 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT00037843 about?

NCT00037843 is a clinical study titled "Iodine I-131 Iodocholesterol, Its Use in Adrenal Screening". This is a clinical research study using I-131 Iodocholesterol which is an experimental radioactive chemical that when injected into the vein, is picked up in the adrenal glands and permits visualization with gamma imaging devices. These images are used in diagnosing a variety of adrenal abnormalitie...

What is the current status of trial NCT00037843?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 114 participants. The study started on 1988-12. Estimated completion is 2007-08.

What interventions are being tested in trial NCT00037843?

The interventions under investigation include: I-131 Iodocholesterol (DRUG).

Who is sponsoring clinical trial NCT00037843?

This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.